Related Experiment Video
Updated: May 28, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
CDH22 expression is reduced in metastatic melanoma
American Journal of Cancer Research
|October 5, 2011
Summary
Reduced expression of Cadherin-like protein 22 (CDH22) is linked to melanoma metastasis and poorer patient survival. This transmembrane glycoprotein
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Cadherin-like protein 22 (CDH22) is a transmembrane glycoprotein involved in cell adhesion and cancer metastasis.
- CDH22 expression is elevated in colorectal cancers, but its role in melanoma is unknown.
Purpose of the Study:
- To investigate the role of CDH22 in melanoma progression.
- To analyze CDH22 expression in melanocytic lesions across different stages.
- To correlate CDH22 expression with clinicopathologic parameters and patient survival.
Main Methods:
- Tissue microarray and immunohistochemistry were used to evaluate CDH22 staining.
- CDH22 expression was assessed in 76 dysplastic nevi, 247 primary melanomas, and 143 metastatic melanomas.
- Statistical analysis correlated CDH22 expression with melanoma stage, thickness, ulceration, and patient survival.
Main Results:
- Metastatic melanomas showed significantly higher rates of negative CDH22 staining compared to nevi and primary melanomas.
- Reduced CDH22 expression was observed in thicker (≥2 mm) and ulcerative melanomas.
- Negative CDH22 staining correlated with advanced AJCC stages (II, III, IV) and poorer 5-year disease-specific survival.
Conclusions:
- Reduced CDH22 expression is associated with melanoma metastasis.
- CDH22 expression levels can serve as a prognostic marker for melanoma patient survival.
- CDH22 may play a role in melanoma progression and warrants further investigation.
